Beyond, the traditional PET nuclides such as 11C and 18F, a number of potential PET nuclide can be produced with a medical cyclotron. This talk will review the current status of production of non-standard Positron Emitting nuclides at Washington University, mainly for use in Positron Emission Tomography (PET). Production of nuclides such as 64Cu, 76Br, 89Zr and 124I will be discussed. Utilization of these nuclides is applied to a variety of medical problems for diagnostics and aims at imaging receptors on cancerous cells. Due to the decay characteristics, image quality will varied dependdn on posoton rangeand concimittant emission of additional gamma rays. The imaging capabilities of such nuclides and some applications will be discussed. In the context of radiopharmaceutical therapy (RPT), a radionuclide is systemically delivered in the circulation with the goal of targeting specific receptors or markers on the tumors and delivering radiation to cancer cells while minimizing radiation exposure to normal tissues. Many of radio-therapy nuclides have excellent therapeutic potential with however poor imaging characteristics. This is especially the case of the potent alpha-emitting nuclides such as 223Ra. This limitation has led to the development of therapeutic pairs, where an imaging nuclide is used in conjunction with a therapy nuclide to provide both imaging and therapy potential.

Production and imaging of non-standard nuclides for diagnostics and therapy

ACS Fall 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.